Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Ptc Therapeutics Inc (PTCT)

347 + Investors. Track Smart Money conviction in PTCT. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +4
Streak
9Q ▲
Buyers last Q
56%

Smart Money Signals — PTCT

Based on 348 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 9 quarters in a row

last 6Q
For 9 consecutive quarters, more hedge funds added PTCT than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
348 hedge funds hold PTCT right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +35% more funds vs a year ago

fund count last 6Q
+90 new funds entered over the past year (+35% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟡

Slight buying edge — 56% buying

209 buying161 selling
Last quarter: 209 funds bought or added vs 161 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
⚠️

Fewer new buyers each quarter (-36 vs last Q)

new funds entering per quarter
Funds opening this position for the first time: 58 → 54 → 99 → 63. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.
🔒

43% of holders stayed for 2+ years

■ 43% conviction (2yr+) ■ 24% medium ■ 33% new
149 out of 348 hedge funds have held PTCT for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
📈

Growing discovery — still being found

52 → 58 → 54 → 99 → 63 new funds/Q
New funds entering each quarter: 58 → 54 → 99 → 63. A growing number of institutions are discovering PTCT each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.
🏛️

Veteran-anchored — 52% veterans vs 39% newcomers

■ 52% veterans ■ 9% 1-2yr ■ 39% new
Entry-cohort mix of 356 holders: 186 (52%) are 2+ year veterans, 31 entered 1–2 years ago, and 139 (39%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
🏆

Elite ownership — 53% AUM from top-100 funds

53% from top-100 AUM funds
55 of 346 holders are among the 100 largest funds by AUM, controlling 53% of total institutional value in PTCT. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.
4.3
out of 10
Moderate Exit Risk
Exit risk score 4.3/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — PTCT

In 2026 Q1, 209 hedge funds were net buyers of PTCT (63 opened a new position, 146 added to an existing one), while 161 reduced or exited (102 trimmed, 59 sold completely) — a 56% buyer ratio, indicating a slight buying edge. This marks 9 consecutive quarters of net institutional buying — a persistent conviction signal. 53% of total institutional value in PTCT is held by top-100 AUM funds, reflecting elite-tier ownership quality. Net fund flow last quarter: +4 funds (more new holders than closures). Total institutional holders: 348.

Hedge Fund Ownership: PTCT

How many hedge funds hold PTCT — quarterly history vs. share price
Quarterly hedge fund ownership of PTCT vs. share price

Market Analysis: PTCT

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: PTCT

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Ptc Therapeutics Inc (PTCT) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much PTCT has moved relative to its sector benchmark (XLV) since the 2026 Q2 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End June 30, 2026 · 45d ago
PTCT
-12.1%
XLV
+5.5%

PTCT outperformed XLV by -17.6% since June 30, 2026.

Since 13F Filing Date August 14, 2026 · 0d ago
PTCT
+0.0%
XLV
+0.0%

Since the filing became public, PTCT outperformed XLV by +0.0% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

26 top-rated funds 2 high-conviction
Consensus
6.2
/ 10
breadth
×
Elite
2.5
/ 10
conviction
Hedge Fund Positioning: PTCT
2026 Q2 Stats Unlock in 5 days 347 + Investors

Track Smart Money conviction in PTCT. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 347 343 1.17%
13F Shares 96M 92M 4.05%
Total Value $6.39B $6.96B -8.28%
New Positions 62 99 -37
Increased Positions 143 122 +21
Closed Positions 58 45 +13
Reduced Positions 101 94 +7
Total Calls 6 7 -14.29%
Total Puts 4 6 -33.33%
PUT/CALL Ratio 0.67 0.86 Bullish

Statistics: PTCT

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

347 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in PTCT. Verified SEC 13F-HR filings.

QUARTER:
2026 Q2 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.
Top 25 PTCT holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Tang Capital Management LLC 5.56% 1,500,000 $122.4M
2 Rtw Investments, LP 5.39% 7,746,415 $631.9M
3 Defilade Capital Management, L.P. 4.74% 433,699 $35.4M
4 Parkman Healthcare Partners LLC 3.64% 435,691 $35.5M
5 Sector Gamma As 1.77% 100,000 $8.2M
6 Boxer Capital Management, LLC 1.23% 200,000 $16.3M
7 Armistice Capital, LLC 1.07% 1,071,395 $87.4M
8 Hood River Capital Management LLC 1.03% 1,738,613 $141.8M
9 Blue Sparrow, LLC /DE 0.83% 1,050,700 $85.7M
10 Driehaus Capital Management LLC 0.68% 1,440,107 $117.5M
11 Armistice Capital, LLC 0.66% 660,000 $53.8M
12 Arrowpoint Investment Partners (Singapore) Pte. Ltd. 0.66% 36,873 $3.0M
13 Dauntless Investment Group, LLC 0.65% 10,193 $831K
14 Rock Springs Capital Management LP 0.65% 162,298 $13.2M
15 Hussman Strategic Advisors, INC. 0.59% 31,500 $2.6M
16 nVerses Capital, LLC 0.56% 4,494 $367K
17 Phocas Financial Corp. 0.52% 46,170 $3.8M
18 Westfield Capital Management Co LP 0.52% 1,956,156 $159.6M
19 Sectoral Asset Management Inc 0.43% 7,470 $609K
20 William Blair Investment Management, LLC 0.42% 1,722,688 $140.5M
21 Capricorn Fund Managers Ltd 0.41% 63,900 $5.2M
22 Flax Pond Capital, LLC 0.32% 6,000 $409K
23 Virtus Investment Advisers, LLC 0.29% 15,476 $1.3M
24 Jupiter Asset Management Ltd 0.29% 707,450 $57.7M
25 Lgl Partners, LLC 0.27% 9,000 $734K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Ptc Therapeutics Inc (PTCT)

What does the Smart Money Trend signal show for PTCT?

Buying streak — 9 quarters in a row: For 9 consecutive quarters, more hedge funds added PTCT than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for PTCT?

Slight buying edge — 56% buying: Last quarter: 209 funds bought or added vs 161 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for PTCT holders?

Elite ownership — 53% AUM from top-100 funds: 55 of 346 holders are among the 100 largest funds by AUM, controlling 53% of total institutional value in PTCT. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held PTCT?

43% of holders stayed for 2+ years: 149 out of 348 hedge funds have held PTCT for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Ptc Therapeutics Inc (PTCT) following the 2026 Q2 hedge fund 13F filings?

As of today, PTCT has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), PTCT has gained -12.1% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →